The hypothesis that the blockage of C5aR1 signaling would be beneficial to COVID-19 may open another important question related to secondary infections that are extremely common in patients with COVID-19 and are a critical threat in the current treatments targeting the immune response (81–85). The gene discussed is C5AR1; the disease is COVID-19.